1,3,4-Oxadiazole Derivatives as Histone Deacetylase Inhibitors
1,3,4-oxadiazole derivatives are developed as selective HDAC6 inhibitors with improved pharmacokinetic properties, addressing diseases like cancer and neurodegenerative disorders by targeting HDAC6 effectively and reducing side effects.
Patent Information
- Application Number
- JP2021562031
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-04-17
- Filing Date
- 2020-04-16
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2040-04-16
AI Technical Summary
There is a need for HDAC6 inhibitors that are potent, selective, and have good pharmacokinetic properties, with minimal off-target side effects, to address various diseases and disorders such as cancer, neurodegenerative diseases, and autoimmune disorders.
Development of 1,3,4-oxadiazole derivatives that act as HDAC6 inhibitors, specifically compounds of formula (I) or their salts, solvates, stereoisomers, or prodrugs, which can be synthesized through methods involving the conversion of tetrazoles to oxadiazoles using difluoroacetic anhydride, and are designed to target HDAC6 selectively.
The compounds demonstrate good brain barrier penetration, improved solubility, and reduced genotoxicity, making them effective for treating HDAC6-related diseases like cancer, neurodegenerative diseases, and autoimmune disorders with minimal side effects.
Smart Images

Figure 0007593647000001 
Figure 0007593647000002 
Figure 0007593647000003
Abstract
Description
[Technical field]
[0001] FIELD OF THEINVENTION The present invention relates to the field of medicinal chemistry, more particularly to the field of histone deacetylases (HDACs). The present invention discloses small organic compounds suitable as HDAC inhibitors, together with methods for their synthesis and their use for treating HDAC-related diseases or disorders. [Background technology]
[0002] 2. Background of the Invention Histone deacetylases (HDACs) are epigenetic regulators that regulate chromatin structure and gene expression and are increasingly also linked to the control of non-epigenetic biological pathways. Altered levels of activity of these metalloenzymes, for example when overexpressed, can lead to dysregulation of essential gene expression and biological processes, eventually resulting in pathogenesis. Indeed, HDACs are well known to play an important role in various diseases and disorders, such as neurological disorders or cancer. Thus, the control of HDAC activity, and in particular by its inhibition, has become an attractive therapeutic strategy for the last decade. Different drug classes of HDAC inhibitors are already on the market (e.g. vorinostat for use in the treatment of lymphoma or valproic acid as an antiepileptic drug) or are in development or in preclinical and clinical trials for several other disorders, such as neurodegenerative diseases.
[0003] HDACs can be classified into classes I–IV according to their exact mechanism of action. Classes I, II, and IV are defined by a zinc-dependent mechanism, while class III HDACs require NAD as a cofactor. + Class II HDACs can be further subdivided into classes IIa (HDACs 4, -5, -7, -9) and IIb (HDACs 6, -10). Although there is some overlap in function, these isoforms generally participate in distinct biological pathways.
[0004] So-called pan-spectrum or broad-spectrum HDAC inhibitors, such as the above-mentioned vorinostat, target various HDACs almost indiscriminately. Not surprisingly, considerable toxicity arises from the use of these inhibitors. In recent years, more attention has been paid to HDAC inhibitors that selectively target HDAC isoforms and have low off-target side effects. Among the selective inhibitors are inhibitors of HDAC6. Dysregulation of HDAC6 has been linked to several pathologies, and inhibition of this isoform has been reported to be useful for targeting cancer, autoimmune and neurodegenerative diseases, inflammation, and several other diseases (Seidel et al., Epigenomics, 2015, 7(1):103-118). European patent EP2483242B1 discloses a series of HDAC6 selective inhibitors for treating cancer, while international patent application WO2018 / 087082 reports their usefulness in treating autoimmune diseases. International patent applications WO2017 / 018805, WO2017 / 018803 and WO2017 / 023133, and European patent application EP3330259 further disclose HDAC6 inhibitors based on an oxadiazole moiety. Summary of the Invention
[0005] In view of this great therapeutic potential, there is a continuing need to develop HDAC6 inhibitors that are potent and selective, and ideally should also possess good pharmacokinetic properties. Moreover, from an industrial point of view, a straightforward synthesis of said compounds is also desirable.
[0006] Summary of the Invention The present inventors have surprisingly discovered a series of compounds which meet the above criteria.
[0007] Thus, in a first aspect, the present invention provides a compound of formula (I) or a salt, solvate, stereoisomer or prodrug thereof [ka] [In the formula, one or two of W, X, Y or Z are N and the remaining ones of W, X, Y and Z are each CH; or each of W, X, Y and Z is CH; R1 is H; unsubstituted or substituted alkyl; or halogen; and R2 is an unsubstituted or substituted, aromatic or non-aromatic heterocyclic ring, said ring containing 1 to 4 nitrogen atoms, and one of these ring nitrogen atoms of the R2 group forms a bond with the remainder of formula (I).
[0008] The inventors have also developed methods by which the compounds of the invention may be readily synthesised.Thus, in a second aspect, the present invention provides a method for the preparation of a compound of the first aspect of the invention.
[0009] The present invention is directed in a further aspect to a pharmaceutical composition comprising a compound of the first aspect of the invention, or a salt, solvate, stereoisomer or prodrug thereof, and at least one pharma- ceutically acceptable excipient.
[0010] Another aspect of the present invention relates to a compound of general formula (I) or a salt, solvate, stereoisomer or prodrug thereof for use as a medicament. The medicament is preferably for use in the prevention or treatment of HDAC6-related diseases or disorders. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0011] Detailed Description of the Invention A first aspect of the present invention relates to a compound of formula (I) or a salt, solvate, stereoisomer or prodrug thereof [ka] [In the formula, one or two of W, X, Y or Z are N and the remaining ones of W, X, Y and Z are each CH; or each of W, X, Y and Z is CH; R1 is H; unsubstituted or substituted alkyl; or halogen; and R2 is an unsubstituted or substituted, aromatic or non-aromatic heterocyclic ring, said ring containing 1 to 4 nitrogen atoms, and one of these ring nitrogen atoms of the R2 group forms a bond with the remainder of formula (I). Regarding.
[0012] One of skill in the art will understand that when W, X, Y or Z is stated to be CH, it is a carbon atom of said CH group that is one of the ring members of a 6-membered ring that contains said W, X, Y or Z, and not a hydrogen atom.
[0013] In one embodiment, two of W, X, Y or Z are N and the remaining ones of W, X, Y and Z are each CH, in other words the six-membered ring comprising W, X, Y and Z is a diazine, in particular it is a pyridazine, pyrimidine or pyrazine. Preferred diazines are pyrimidines, more preferably pyrimidines where X and Y are N and Z and W are CH.
[0014] In a preferred embodiment, one of W, X, Y or Z is N and the remaining ones of W, X, Y and Z are each CH, in other words, the six-membered ring comprising W, X, Y and Z is pyridine. In a particular embodiment, it is pyridine where Z or W is N and the remaining ones of W, X, Y and Z are each CH. In a more particular embodiment, it is pyridine where X or Y is N and the remaining ones of W, X, Y and Z are each CH.
[0015] In another preferred embodiment, W, X, Y and Z are all CH.
[0016] R1 is H; unsubstituted or substituted alkyl; or halogen.
[0017] In the context of the present invention, the term "alkyl" refers to a straight, branched or cyclic hydrocarbon chain consisting of carbon and hydrogen atoms, containing no unsaturation, having 1 to 6 carbon atoms (C1-C6 alkyl), preferably 1 to 3 carbon atoms (C1-C3 alkyl), and connected to the rest of the molecule by a single bond. Non-limiting examples of alkyl are methyl, ethyl, n-propyl, i-propyl, cyclopropyl, n-butyl, t-butyl, n-pentyl or cyclohexyl. Particular preferred alkyl groups are methyl or ethyl. The methyl group is particularly preferred.
[0018] As used herein, the term substituted indicates that the specified group may be substituted in one or more available positions with one or more substituents.
[0019] When R1 is a substituted alkyl, the substituent may be a halogen. A preferred halogen is Cl or F. In a particular embodiment, the halogen is Cl. In another particular embodiment, the halogen is F.
[0020] When R1 is a halogen, the preferred halogen is Cl or F. In a particular embodiment, the halogen is Cl. In another particular embodiment, the halogen is F.
[0021] The term "halogen" as used in this disclosure refers to bromine, chlorine, iodine or fluorine.
[0022] In a preferred embodiment, R1 is H.
[0023] In certain embodiments, any of the R1 embodiments above is combined with any of the W, X, Y, or Z embodiments above.
[0024] In certain preferred embodiments, the six-membered ring comprising W, X, Y and Z is pyridine, where X or Y is N and the remainder of W, X, Y and Z are each CH; and R1 is H.
[0025] In another preferred specific embodiment, W, X, Y and Z are all CH; and R 1 is H.
[0026] R2 is an unsubstituted or substituted, aromatic or non-aromatic heterocyclic ring, which ring contains 1 to 4 nitrogen atoms, and one of these ring nitrogen atoms of the R2 group forms a bond with the remainder of formula (I).
[0027] In the context of the present invention, the terms "heterocycle" and "heterocyclic ring" are used interchangeably and refer to a 3-14 membered, preferably 5-10 membered, ring comprising or consisting of carbon and nitrogen atoms. A heterocyclic ring can be an aromatic ring (also referred to herein as a heteroaryl ring or heteroaryl); or a non-aromatic ring, including both saturated or partially unsaturated rings, as well as a polycyclic ring, including at least one ring that is aromatic and at least one other ring that is not aromatic. A heterocyclic ring can be monocyclic or polycyclic, e.g., monocyclic, bicyclic or tricyclic, or preferably, monocyclic or bicyclic. A polycyclic ring is also referred to in the art as a polycyclic ring system. In certain embodiments, a polycyclic ring is fused, spirocyclic or bridged, or exhibits two or more of these types of ring connections. In certain embodiments, a polycyclic ring is a fused or bridged polycyclic ring, more preferably a fused polycyclic ring. The bicyclic ring is preferably a fused bicyclic ring.
[0028] In a preferred embodiment, the heterocyclic ring is a heteroaryl ring.
[0029] In a preferred embodiment, the heteroaryl ring is a 5-membered monocyclic heteroaryl ring, such as pyrrolyl; diazolyl, such as imidazolyl or pyrazolyl; triazolyl, such as 1,2,3-triazolyl or 1,2,4-triazolyl; or tetrazolyl. More preferably, the heteroaryl ring is an imidazolyl or 1,2,3-triazolyl ring, more preferably a 1,2,3-triazolyl ring.
[0030] In certain preferred embodiments, the six-membered ring comprising W, X, Y and Z is pyridine, where X or Y is N and the remainder of W, X, Y and Z are each CH; R1 is H; and R2 is imidazolyl.
[0031] In another preferred specific embodiment, W, X, Y and Z are all CH; R1 is H; and R2 is imidazolyl.
[0032] In certain preferred embodiments, the six-membered ring comprising W, X, Y and Z is pyridine, where X or Y is N and the remainder of W, X, Y and Z are each CH; R1 is H; and R2 is 1,2,3-triazolyl.
[0033] In another preferred specific embodiment, W, X, Y and Z are all CH; R1 is H; and R2 is 1,2,3-triazolyl.
[0034] A preferred 1,2,3-triazolyl is 1H-1,2,3-triazolyl.
[0035] In certain embodiments, the heteroaryl ring is a 6-membered monocyclic heteroaryl ring, eg, pyridyl, diazinyl, triazinyl, or tetrazinyl.
[0036] In certain embodiments, the 6-membered ring comprising W, X, Y, and Z is pyridine, where X or Y is N and the remainder of W, X, Y, and Z are each CH; R1 is H; and R2 is a 6-membered monocyclic heteroaryl ring.
[0037] In certain embodiments, W, X, Y and Z are all CH; R1 is H; and R2 is a 6-membered monocyclic heteroaryl ring.
[0038] In a preferred embodiment, the heteroaryl ring is a 9-membered bicyclic heteroaryl ring. Preferably, the 9-membered bicyclic heteroaryl ring is formed by the fusion of a 5-membered ring with a 6-membered ring. More preferably, the nitrogen atom of the 5-membered ring forms a bond with the remainder of formula (I).
[0039] In preferred embodiments, in these fused rings, the fused bond does not contain a nitrogen atom, i.e., it is a carbon-carbon bond, which means that if it is a nitrogen atom of a 5-membered ring that forms a bond with the remainder of formula (I), the 6-membered ring may contain 0-3 nitrogen atoms (not including nitrogen atoms in the ring structure, i.e., not included in the substituents of the ring).
[0040] In a preferred embodiment, the 6-membered ring does not contain a nitrogen atom (including fused bonds), and therefore the 1-4 nitrogen ring atoms of R2 must be 1-3 nitrogen ring atoms, all of which must be contained in the 5-membered ring (not including fused bonds). Examples of such heteroaryl rings are indolyl, benzimidazolyl, indazolyl and benzotriazolyl rings. Most preferably, the heteroaryl ring is a benzimidazolyl or benzotriazolyl ring.
[0041] In any of these embodiments, the five-membered ring is an imidazolyl or a 1,2,3-triazolyl ring, and it is more preferably a 1,2,3-triazolyl ring.
[0042] In certain preferred embodiments, the six-membered ring comprising W, X, Y and Z is pyridine where X or Y is N and the remainder of W, X, Y and Z are each CH; R1 is H; and R2 is a benzimidazolyl or benzotriazolyl ring.
[0043] In certain embodiments, W, X, Y and Z are all CH; R1 is H; and R2 is a benzimidazolyl or benzotriazolyl ring.
[0044] In some embodiments, the heteroaryl ring is a 10-membered bicyclic heteroaryl ring. Preferably, the 10-membered bicyclic heteroaryl ring is formed by the fusion of a 6-membered ring with a 6-membered ring, and more preferably, one of the 6-membered rings does not contain a nitrogen ring atom (including the fused bond).
[0045] In certain embodiments, the 6-membered ring comprising W, X, Y and Z is pyridine, where X or Y is N, and the remainder of W, X, Y and Z are each CH; R1 is H; and R2 is a 10-membered bicyclic heteroaryl ring as defined above.
[0046] In certain embodiments, W, X, Y and Z are all CH; R1 is H; and R2 is a 10-membered bicyclic heteroaryl ring as defined above.
[0047] In any of the above embodiments, the R2 heterocyclic ring may be unsubstituted or it may be substituted with one substituent at one or more available positions, or with two or more substituents where available.
[0048] Suitable R2 substituents include: · Alkyl, alkoxy, thioalkoxy, and their halogenated derivatives; ·halogen; · Phenyl and phenyl substituted with alkyl, alkoxy, thioalkoxy or their halogenated derivatives, or halogen; =O, -C(=O)R a Or -C(=O)OR a (R a is an alkyl group as defined above), or a halogenated derivative thereof; and Pyridyl and pyridyl substituted with alkyl, alkoxy, thioalkoxy or their halogenated derivatives or halogen; Thiophenyl, furan or pyrrole, and thiophenyl, furan or pyrrole substituted with alkyl, alkoxy, thioalkoxy or their halogenated derivatives or halogens Examples include:
[0049] The R2 substituent is preferably a relatively non-polar group. Thus, in some embodiments, the R2 substituent is: · Alkyl, alkoxy, thioalkoxy, and their halogenated derivatives; ·halogen; Phenyl and alkyl, alkoxy, thioalkoxy or their halogenated derivatives, or phenyl substituted with halogen is selected from.
[0050] The term "alkyl" has the meaning defined above. A preferred alkyl group is ethyl or methyl, and even more preferably it is methyl.
[0051] In the context of the present invention, the term "alkoxy" refers to a group of the formula -OR a In the formula, R a is an alkyl group as defined above. A preferred alkoxy group is ethoxy or methoxy, and even more preferably, it is methoxy. In different embodiments, the alkoxy group refers to an alkyl group in which one of the non-terminal hydrocarbon units of the alkyl chain is replaced by an oxygen atom.
[0052] In the context of the present invention, the term "thioalkoxy" refers to a group of the formula -SR a In the formula, R a is an alkyl group as defined above. A preferred thioalkoxy group is thioethoxy (-SEt) or thiomethoxy (-SMe), and even more preferably it is thiomethoxy. In different embodiments, the thioalkoxy group refers to an alkyl group in which one of the non-terminal hydrocarbon units of the alkyl chain is replaced by a sulfur atom.
[0053] In the context of the present invention, the term "halogenated" refers to halogen substitution, in other words, any of the above alkyl, alkoxy, thioalkoxy groups may be fully or partially substituted with halogen atoms. Preferably, the halogen atom is F or Cl, more preferably, it is F. A preferred specific halogenated substituent is the trifluoromethyl (-CF3) group.
[0054] The term "halogen" has the meaning further defined above.Preferred halogens are Cl and F, both when halogen is an R2 substituent, and when halogen is a substituent of phenyl or pyridyl if phenyl or pyridyl is an R2 substituent.In some embodiments, R2 group, or when it is an R2 substituent, phenyl or pyridyl, is monohalogenated, dihalogenated or trihalogenated, for example, monochlorinated, dichlorinated or trichlorinated, or monofluorinated, difluorinated or trifluorinated.
[0055] In particularly preferred embodiments, the R2 substituent is halogen or phenyl substituted with a halogen as defined above.
[0056] In a preferred embodiment, R2 is a 5-membered monocyclic heteroaryl ring as defined in any of the above embodiments, which is substituted with at least one relatively non-polar group as defined in any of the above embodiments, preferably phenyl or phenyl substituted with alkyl, alkoxy, thioalkoxy or their halogenated derivatives.In a highly preferred embodiment, R2 is a 5-membered monocyclic heteroaryl ring as defined in any of the above embodiments, which is substituted with at least one phenyl group, for example, 1 or 2 phenyl groups, each of which may be halogenated, for example, monohalogenated, dihalogenated or trihalogenated, for example, monochlorinated, dichlorinated or trichlorinated, or monofluorinated, difluorinated or trifluorinated.Optionally, in this highly preferred embodiment, the 5-membered monocyclic heteroaryl ring is also substituted with halogen as defined in any of the above embodiments.
[0057] In a preferred embodiment, R2 is a 9-membered bicyclic heteroaryl ring as defined in any of the above embodiments, which is substituted with at least one relatively non-polar group selected from alkyl, alkoxy, thioalkoxy, and their halogenated derivatives; and halogen, as defined in any of the above embodiments.In a highly preferred embodiment, R2 is a 9-membered monocyclic heteroaryl ring as defined in any of the above embodiments, which is substituted with halogen, for example, monohalogenated, dihalogenated or trihalogenated, for example, monochlorinated, dichlorinated or trichlorinated, or monofluorinated, difluorinated or trifluorinated.
[0058] In a preferred embodiment, the compound of formula (I) is a compound of formula (Ia): [ka] [In the formula, R1, W, X, Y and Z are as defined in any of the above embodiments; and R3 and R4 are each independently selected from a relatively non-polar group as defined in any of the above embodiments, or R3 and R4 together with the triazole 4 and 5 positions form a 6-membered ring as defined in any of the above embodiments. In a particularly preferred embodiment, R4 is H. The relatively non-polar group is preferably phenyl or alkyl, alkoxy, thioalkoxy or halogenated derivatives thereof, or substituted with halogen, most preferably phenyl substituted with halogen.]
[0059] In a preferred particular embodiment, the compound of formula (I) is a compound of formula (Ia1): [ka] [In the formula, R1, W, X, Y and Z are as defined in any of the above embodiments; R3 is selected from a relatively non-polar group as defined in any of the above embodiments, preferably phenyl or alkyl, alkoxy, thioalkoxy or halogenated derivatives thereof, or substituted with halogen, most preferably phenyl substituted with halogen; and Hal is a halogen as defined in any of the above embodiments.
[0060] In some embodiments, the compound of formula (I) is selected from the following list:
[0061] [Table 1] TIFF0007593647000006.tif233153TIFF0007593647000007.tif228158TIFF00075936470 00008.tif207149TIFF0007593647000009.tif230152TIFF0007593647000010.tif213152 TIFF0007593647000011.tif216156TIFF0007593647000012.tif227160TIFF00075936470 00013.tif212153TIFF0007593647000014.tif230151TIFF0007593647000015.tif141154
[0062] The compounds of formula (I) may be in the form of a salt, solvate, stereoisomer or prodrug.
[0063] The term "salt" should be understood as any form of a compound of formula (I) according to the invention that is in ionic form or is in ionic form and is associated with a counterion (cation or anion). Preferably, the salt is a pharma- ceutically acceptable salt, i.e. a physiologically acceptable salt, meaning that it is not toxic, especially as a result of the counterion, when used in a suitable manner (i.e. in a reasonable medical dose) for the treatment according to the invention.
[0064] The preparation of salts can be achieved by methods known in the art. Generally, such salts are prepared by reacting the free base form of the compound of the present invention with a suitable base or acid in water or an organic solvent or a mixture of both. Generally, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile are preferred.
[0065] The term "solvate" should be understood to mean any compound of formula (I) according to the present invention that is non-covalently bound to another molecule (usually a polar solvent), including in particular hydrates and alcoholates such as methanolates.Preferred solvates are hydrates.Preferably, the solvate is a pharma-ceutically acceptable solvate, i.e., it is not toxic, especially as a result of the solvate molecule, when used in a suitable manner (i.e., in a reasonable medical dose) for treatment according to the present invention.
[0066] As used herein, the term "stereoisomer" refers to the enantiomer, diastereomer, or mixture thereof, such as racemate, of the compound of formula (I) according to the present invention.Similarly, this term also includes the geometric isomers about any double bond present in the compound of formula (I), i.e., (E)-isomer and (Z)-isomer (trans and cis isomer).In addition, this term also includes the rotational isomers of the compound of formula (I).
[0067] Any compound of formula (I) according to the present invention may exist in different tautomeric forms. Specifically, the term "tautomer" refers to one of two or more structural isomers of a compound of formula (I) that exist in equilibrium and are easily converted from one isomeric form to another. Common tautomeric pairs are amine-imine, amide-imidic acid, or keto-enol.
[0068] The term "prodrug" refers to derivatives of compounds of formula (I) that are converted in vivo, such as by enzymatic hydrolysis, to compounds of formula (I).
[0069] Another aspect of the present invention refers to various methods for the preparation of compounds of formula (I) as defined above. All references to W, X, Y, Z, R1, R2, R3, R4, Hal and any other variable positions are as defined above for the compounds of the present invention.
[0070] The process of the invention involves converting a tetrazole of formula (II) to an oxadiazole of formula (I) in the presence of difluoroacetic anhydride (DFAA). The reaction is a one-pot acylation and pyrolysis with loss of N2. DFAA is added in a molar excess, such as a 5-30 fold molar excess, relative to the tetrazole.
[0071] The reaction is generally carried out in a temperature range of 40 to 120° C. In one embodiment, when one or two of W, X, Y, or Z are N and the remaining of W, X, Y, and Z are each CH, the temperature range is at the lower end of the range, e.g., 40 to 80° C. In another embodiment, when W, X, Y, and Z are each CH, the temperature range is at the upper end of the range, e.g., 80 to 120° C.
[0072] Examples of suitable solvents for the reaction are aromatic hydrocarbons such as benzene, toluene or xylene; chlorinated hydrocarbons such as dichloromethane or chloroform; or acetone.However, in a preferred embodiment, the reaction is carried out in the absence of these solvents, since DFAA serves as both a solvent and an acylating agent.Once the reaction is complete, the oxadiazole of formula (I) is isolated by standard methods in the art, such as organic extraction and silica column chromatography.
[0073] DFAA is readily available commercially, such as from Fluirochem Ltd. (#034690).
[0074] The tetrazoles of formula (II) can be obtained in several ways. [ka]
[0075] In certain embodiments, the tetrazole of formula (II) is obtained as described above in Scheme I (also referred to herein as Method A), which involves reacting the nitrile (III) with an azide ion in the presence of an acid addition salt of ammonia or an amine.
[0076] Representative sources of azide ions are metal azides, particularly alkali metal azides, such as sodium azide, or trialkylsilyl azides having 1 to 4 carbon atoms in each of the alkyl groups, such as trimethylsilyl azide and triethylsilyl azide. Sodium azide is particularly preferred. The molar ratio of azide to the nitrile of formula (III) is generally maintained in the range of about 1:1 to about 6:1.
[0077] Examples of suitable acid addition salts are salts with inorganic acids, in particular hydrochloric acid, and organic acids, such as alkanesulfonic acids, such as methane and ethanesulfonic acid, p-toluenesulfonic acid or benzenesulfonic acid. Examples of suitable amines for forming acid addition salts are tertiary amines, such as trimethylamine, N,N-dimethylaniline, N-methylpiperidine or N-methyl-morpholine. Ammonium chloride is particularly preferred. The molar ratio of this salt to the nitrile of formula (III) is generally maintained at about 1:1 to about 6:1, and is generally at least equimolar with the azide.
[0078] Metal Lewis acids can be used as reaction catalysts. The metal coordinates to the nitrile and azide groups, lowering the barrier to nucleophilic attack by the azide. Various catalysts have been reported in the art, including lithium or copper halide salts, such as lithium chloride, or copper iodide or zinc oxide. The catalyst is preferably lithium chloride. The molar ratio of catalyst to the nitrile of formula (III) is generally maintained in the range of about 1:2 to about 2:1.
[0079] This reaction is generally carried out in a reaction inert solvent.Examples of reaction inert solvents suitable for this method are N,N-dimethylformamide (DMF), halogenated hydrocarbons such as dichloromethane (DMC) or chloroform; ethers such as dioxane, tetrahydrofuran (THF); benzene or pyridine.DMF is particularly preferred.
[0080] This reaction is generally carried out in the temperature range of 50 to 120°C.
[0081] Acid addition salts of ammonia or amines, as well as azides and metal catalysts are readily commercially available, for example, from Sigma-Aldrich (ammonium chloride, #254134; sodium azide, #S2002; lithium chloride, #L4408).
[0082] In certain embodiments, the nitrile of formula (III) is obtained by reacting an alkyl halide of formula (V) with a heterocyclic amine of formula (IV) in the presence of a base.
[0083] A variety of bases can be used for this alkylation, such as alkali metal hydrides, e.g., NaH; alkali metal hexamethyldisilazane (HMDS), e.g., LiHMDS; lithium diisopropylamide (LDA); or alkali metal carbonates, e.g., Na2CO3. Preferred bases are NaH and Na2CO3. 1-3 molar equivalents of base are generally used.
[0084] The reaction is preferably carried out in an aprotic solvent such as THF, dioxane, DMF or dimethylsulfoxide (DMSO). The preferred solvent is DMF.
[0085] Preferably, the heterocyclic amine of formula (IV) is first treated with a base to deprotonate the heterocyclic amine and then the halide of formula (V) is added.
[0086] The reaction can be carried out at temperatures ranging from -78°C to the reflux temperature of the solvent used. Upon completion of the reaction, the nitrile of formula (III) is isolated by methods standard in the art, such as organic extraction and silica column chromatography.
[0087] The halide of formula (V) is generally a bromide, iodide or chloride, more preferably it is a bromide.
[0088] Halides of formula (V) are commercially available, such as from Sigma Aldrich (4-(bromomethyl)benzonitrile; #144061) or Matrix Scientific (6-bromomethyl-nicotinonitrile; #058787).
[0089] Heterocyclic amines of formula (IV) are also readily available commercially, such as from Sigma Aldrich (imidazole, #56750; tetrazole, #88185; indole, #I3408).
[0090] Bases are also readily available commercially, such as from Sigma Aldrich (sodium hydride; #223441).
[0091] However, in certain embodiments, the halides of formula (V) can also be prepared by halogenation of the corresponding alkyl compounds of formula (VI), ie, by reaction of an alkyl compound of formula (VI) with a halogenating agent.
[0092] The halogenating agent may be any conventional halogenating agent. Examples of such halogenating agents are brominating agents such as bromine, hydrogen bromide, N-bromosuccinimide (NBS), copper bromide, tetramethylammonium tribromide, trifluoroacetyl hypobromite, dibromoisocyanuric acid, etc.; iodinating agents such as iodine, iodine chloride, trifluoroacetyl hypoiodite, and N-iodosuccinimide; or chlorinating agents such as chlorine, thionyl chloride, N-chlorosuccinimide, or copper chloride. Among these, N-bromosuccinimide, N-iodosuccinimide, and N-chlorosuccinimide are preferred. The amount of halogenating agent is preferably 1 to 4 molar equivalents relative to the alkyl compound of formula (VI).
[0093] Solvents that can be used in the halogenation reaction include hydrocarbons such as heptane, hexane, cyclohexane, pentane, toluene, and xylene; ethers such as diethyl ether, THF, or dioxane; halogenated hydrocarbons such as chloroform or DCM; DMF, ethyl acetate, DMSO, or MeCN. The solvent is preferably DMF.
[0094] The above halogenation reaction is preferably carried out in the presence of a radical initiator. Examples of the radical initiator include 2,2'-azobisisobutyronitrile (AIBN), 1,1'-azobis(cyclohexane-1-carbonitrile) (V-40), benzoyl peroxide or (PhCOO)2. A preferred radical initiator is AIBN. The amount of the radical initiator is preferably 0.01 to 0.5 molar equivalents relative to the alkyl compound of formula (VI).
[0095] The reaction is generally carried out at a temperature between 0 and 100° C. Upon completion of the reaction, the halide of formula (V) is isolated by methods standard in the art, such as organic extraction and silica column chromatography.
[0096] Alkyl compounds of formula (VI) are readily commercially available, such as from Sigma Aldrich (p-tolunitrile; #132330) or Acros Organics (5-cyano-2-methylpyridine; #15259816); halogenating agents and radical initiators are likewise readily commercially available, such as from Sigma-Aldrich (N-chlorosuccinimide, #109681; AIBN, #441090).
[0097] In a different embodiment, the tetrazole of formula (II) is obtained as described below in Scheme II (also referred to herein as Method B). [ka]
[0098] Method B applies in particular to compounds of formula (Ia) above.
[0099] The tetrazoles of formula (IIa) can be obtained from the nitriles (IIIa) in a manner similar to that described above for the conversion of the nitriles (III) to the tetrazoles (II).
[0100] The nitrile (IIIa) can be prepared from the azide compound (IVa) by reacting it with an alkyne of formula (X), which is a 1,3-cycloaddition between the azide and alkyne functional groups.
[0101] This reaction generally uses a copper(I) catalyst. The Cu(I) catalyst, such as copper iodide, chloride or bromide, preferably copper iodide, can be used directly or, alternatively, a Cu(II) species, such as copper sulfate or acetate, can be used together with a reducing agent, such as an ascorbate, e.g., sodium ascorbate, and the two react to generate the Cu(I) catalyst species in situ. When the copper(I) species is used directly, sonication and / or base are usually relied upon to enhance the reaction rate. Examples of suitable bases are amine bases, such as trimethylamine, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) or N,N-diisopropylethylamine (DIPEA). The preferred initiator is DIPEA.
[0102] The cycloaddition can be carried out in a variety of solvents, such as protic solvents, for example alcohols or water; or aprotic solvents, for example THF, DMSO, DMF, toluene or acetone. The solvent is preferably DMF.
[0103] The reaction is usually carried out with equimolar amounts of azide (IVa) and alkyne (X), and when a copper catalyst is used, it is generally added in catalytic amounts. When a base is relied upon, it is usually used in molar excess.
[0104] The cycloaddition can be carried out under mild conditions such as room temperature (20-25° C.), but may also be carried out at higher temperatures or under microwave irradiation. Upon completion of the reaction, the nitrile of formula (IIIa) can be isolated by methods standard in the art such as organic extraction and silica column chromatography.
[0105] Copper catalysts and bases are readily available commercially, such as from Celtic Chemicals (cuprous iodide, #P400) or Sigma-Aldrich (DIPEA, #387649).
[0106] The azide compounds of formula (IVa) can be prepared by reacting a halide of formula (V) with an azide. The conditions are carefully selected so that cycloaddition between the azide and the nitrile group of the azide compound of formula (IVa) does not occur. This is achieved by carrying out the conversion in a system similar to that used for the conversion of (V) to (VIIa), but with much milder conditions. In particular, the reaction is carried out at room temperature and does not use ammonia or an acid addition salt of an amine, or is catalyzed.
[0107] The halides of formula (V) and alkyl compounds of formula (VI) can be prepared as described above.
[0108] In an alternative route according to method B, the tetrazole of formula (IIa) is prepared from an azide compound of formula (VIIa) and an alkyne of formula (X) using the same reactions as described above for the conversion of the azide compound of formula (IVa) to the nitrile of formula (IIIa).
[0109] Depending on whether three independent reactions are carried out, namely nucleophilic substitution introducing an N3 group, and nitrile cycloaddition and alkyne cycloaddition, the route proceeding through intermediate (VIIa) provides a one-step N3 nucleophilic substitution and nitrile cycloaddition, rather than the route proceeding through intermediates (IVa) and (IIIa). This one-step double conversion can be achieved by using the same reaction as described above for the conversion of the nitrile of formula (IIIa) to the tetrazole of formula (IIa), provided that at least two molar equivalents of azide relative to the halide of formula (V) are ensured. Surprisingly, it has been found that the route proceeding through intermediates (IVa) and (IIIa) is particularly suitable for compounds in which one or two of W, X, Y or Z are N, and the remaining ones of W, X, Y and Z are each CH, since it gives a better overall yield than the route proceeding through intermediate (VIIa).
[0110] In a different embodiment, the tetrazole of formula (II) is obtained as described below in Scheme III (also referred to herein as Method C). [ka]
[0111] Method C applies in particular to compounds of formula (Ia1) above.
[0112] The halogenated tetrazoles of formula (IIa1) can be obtained from the halogenated nitriles (IIIa1) in a manner similar to that described above for the conversion of the nitriles (IIIa) to the tetrazoles (IIa).
[0113] The halogenated nitrile of formula (IIIa1) can be prepared from the cuprous acetylenide of formula (VIII) by reacting it with an azide compound of formula (IVa) in the presence of a halogenating agent.
[0114] The halogenating agent can be, for example, those described above for the conversion of an alkyl compound of formula (VI) to a halide of formula (V), however, the halogenating agent is preferably an N-halosuccinimide.
[0115] The azide compound, cuprous acetylenide and halogenating agent can be added simultaneously to the reaction mixture, however, better yields of the halogenated nitrile of formula (IIIa1) are obtained if the azide compound is first reacted with cuprous acetylenide to form the 1,2,3-triazole cuprous intermediate and then the halogenating agent is added.
[0116] The azide compound, cuprous acetylenide, and halogenating agent can be used in equimolar amounts, but the azide compound and halogenating agent are usually used in an extremely slight excess amount, such as 1.1 to 2 times the molar amount of the azide compound.
[0117] Commonly used solvents for the transformation are chlorinated hydrocarbons such as DCM, dichloroethane or chloroform.
[0118] The reaction may proceed at room temperature or at higher temperatures, for example, from 20° C. to the reflux temperature of the solvent. If halogenation at other positions, for example at the R1 position, is not desired, the conditions can be adjusted to avoid this, for example by using milder reaction conditions, for example by carrying out the reaction at room temperature rather than at reflux, or by shortening the reaction time.
[0119] Upon completion of the reaction, the halogenated nitrile of formula (IIIa1) can be isolated by methods standard in the art, such as organic extraction and silica column chromatography.
[0120] The cuprous acetylenide of formula (VIII) can be obtained by reacting the corresponding alkyne of formula (IX) with a copper(I) species.
[0121] Representative Cu(I) species are copper(I) halides, such as copper iodide or copper chloride. Alternatively, a Cu(II) species, such as copper sulfate, can be used together with a reducing agent, such as hydroxylammonium chloride. The Cu(I) species is preferably CuI.
[0122] The reaction is generally carried out by dissolving the copper halide in a solvent that is less acidic than the alkyne, such as an ether solvent, e.g., diethyl ether, THF; chlorinated and non-chlorinated hydrocarbons, e.g., dichloromethane or toluene; or trimethylamine, aqueous ammonia, or ammonium hydroxide. Preferably, the reaction is carried out in ammonium hydroxide.
[0123] Alkynes of formula (IX) or (X) are readily commercially available, such as from Sigma Aldrich (phenylacetylene, #117706; ethynyltoluene, #206504; or chloro-4-ethynylbenzene, #206474).
[0124] Copper(I) or copper(II) species suitable for the above reaction can also be purchased commercially, such as from Sigma Aldrich (copper(I) chloride, #651745; copper(II) sulfate, #451657).
[0125] In another route according to method C, the tetrazole of formula (IIa1) is prepared directly from the azide of formula (VIIa) and the cuprous acetylenide of formula (VIII) using the same reaction as described above for the reaction of the azide of formula (IVa) with the cuprous acetylenide of formula (VIII) to give the halogenated nitrile of formula (IIIa1). Unexpectedly, it has been found that the route proceeding via intermediates (IVa) and (IIIa1) is particularly suitable for compounds in which one or two of W, X, Y or Z are N and the remaining ones of W, X, Y and Z are each CH, since it gives better overall yields than proceeding via intermediate (VIIa).
[0126] Variations of the above synthetic methods within the common general knowledge of a person skilled in the art can be used to arrive at the various compounds of formula (I) to which the present invention pertains.
[0127] For example, when R1 is a halogen, any of the above oxadiazoles of formula (I) can be readily halogenated using the halogenation conditions as described above.
[0128] Another aspect of the present invention relates to a pharmaceutical composition comprising at least one compound of formula (I), or a salt, solvate, stereoisomer or prodrug thereof, and at least one pharma- ceutically acceptable excipient. The term "excipient" refers to a component of a drug compound other than the active ingredient (as defined by the European Medicines Agency-EMA). They preferably include "carriers, adjuvants and / or vehicles". Carriers are the form in which a substance is incorporated to improve the delivery and efficacy of a drug. Drug carriers are used in drug delivery systems, such as sustained release technologies, to prolong in vivo drug action, reduce drug metabolism, or reduce drug toxicity. Carriers are also used to enhance the efficacy of drug delivery to the target site of pharmacological action. Adjuvants are substances added to drug formulations that affect the action of the active ingredient in a predicted manner. A vehicle is an excipient or substance, preferably without therapeutic activity, used as a medium to provide bulk for the administration of a medicament (Stedman's Medical Spellchecker® 2006 Lippincott Williams & Wilkins). Such pharmaceutical carriers, adjuvants or vehicles can be sterile liquids, such as water and oils (including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc.). Suitable pharmaceutical carriers are described in "Pharmaceutical Sciences" by EW Martin. The choice of these excipients and the amounts used depends on the form of application of the pharmaceutical composition. The pharmaceutical composition according to the invention may be in any form suitable for its application in humans and / or animals, preferably humans (including infants, children and adults), and may be prepared by means of conventional methods known to those skilled in the art, such as those described or described in the Spanish and United States Pharmacopoeias and equivalent reference texts.
[0129] The pharmaceutical compositions of the present invention may be in any form suitable for drug administration, for example, intraperitoneal, intramuscular, intraarticular, intravenous, intraarterial, intravesical, intraosseous, intracavity, pulmonary, buccal, sublingual, ocular, intravitreal, intranasal, transdermal, rectal, vaginal, oral, epidural, intrathecal, intraventricular, intracerebral, intraventricular, intracisternal, intraspinal, perispinal, intracranial or topical. The dosage form suitable for oral administration may be a tablet and a capsule, and may contain conventional excipients known in the art, such as binders, such as syrup, gum arabic, gelatin, sorbitol, gum tragacanth or polyvinylpyrrolidone; fillers, such as lactose, sugar, corn starch, calcium phosphate, sorbitol or glycine; lubricants for tablet manufacture, such as magnesium stearate; disintegrants, such as starch, polyvinylpyrrolidone, sodium starch glycolate or microcrystalline cellulose; or pharma-ceutically acceptable wetting agents, such as sodium lauryl sulfate.The dosage form suitable for parenteral administration may be a sterile solution, suspension or lyophilized product.Suitable excipients, such as fillers, buffers or surfactants, may be used.
[0130] Another aspect of the present invention relates to a compound of formula (I) or a salt, solvate, stereoisomer or prodrug thereof for use as a medicament. In a preferred embodiment, the medicament is for use in the prevention or treatment of HDAC6-related diseases or disorders.
[0131] Similarly, the present invention also relates to a method for preventing or treating an HDAC6-associated disease or disorder in a subject in need thereof, comprising administering to the subject a compound of formula (I) or a pharma- ceutically acceptable salt, solvate, stereoisomer or prodrug thereof.
[0132] Similarly, the present invention also relates to the use of a compound of formula (I) or a pharma- ceutically acceptable salt, solvate, stereoisomer or prodrug thereof in the manufacture of a medicament for the prevention or treatment of an HDAC6-related disease or disorder.
[0133] Similarly, the present invention also relates to the use of a compound of formula (I) or a pharma- ceutically acceptable salt, solvate, stereoisomer or prodrug thereof for preventing or treating a HDAC6-related disease or disorder.
[0134] As used herein, HDAC6-related disease or disorder refers to disease or disorder that is at least partially mediated by HDAC6.Examples of such diseases or disorders are reviewed in Van Helleputte et. al, 2014, Research and Reports in Biology, 5:1-13; Seidel et al., Epigenomics, 2015, 7(1):103-118; Ke et al., Mol Med, 2018, 24:33; Jian et al., Neuroscience Letters, 2017, 658:114-120.
[0135] In certain embodiments, the HDAC6-associated disease or disorder is selected from cancer, e.g., prostate cancer, multiple myeloma, or glioblastoma multiforme; inflammation; a neurodegenerative disease, e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinal muscular atrophy, or Charcot-Marie-Tooth disease; an autoimmune disease, e.g., multiple sclerosis, rheumatoid arthritis, or autoimmune hepatitis; a peripheral neuropathy, e.g., chemotherapy-induced or diabetic neuropathy; a major depressive disorder; a renal disease, e.g., autosomal dominant polycystic kidney disease, lupus nephritis, or acute kidney injury; or transplant rejection.
[0136] In addition to their ability to selectively target HDAC6, the compounds of the present invention have unexpectedly good brain barrier permeability.Therefore, a preferred embodiment of the present invention relates to the compound of formula (I) for use in treating or preventing central nervous system HDAC6-related diseases or disorders, such as the above-mentioned neurodegenerative diseases or disorders, multiple sclerosis, or depression.
[0137] In the context of the present invention, the term "treatment" refers to the amelioration or elimination of a disease or disorder.
[0138] In the context of the present invention, the term "prevention" refers to the reduction or elimination of the risk of the development, occurrence or recurrence of a disease or disorder.
[0139] The compound of the present invention can be used with at least another drug to provide combination therapy. The other drug or drugs can be part of the same composition or can be provided as a separate composition, and can be administered at the same time or at different times. In some embodiments, two or more compounds of the present invention can be used in combination with each other, such as in the case of Example 12, 57 or 58 described herein. In such combinations, for example, in the case of Example 12, 57 or 58, different compounds of the present invention can be present in different amounts.
[0140] Additionally, unexpectedly, compounds of the invention have been found to have good solubility profiles as well as improved genotoxicity, properties that HDAC6 inhibitors often lack.
[0141] In general, the compound of the present invention is used in a therapeutically effective amount.What constitutes a therapeutically effective amount of a given compound of the present invention can be established by a medical professional based on several factors, such as the relative effectiveness of the selected compound, the severity of the disorder being treated, or the weight or age of the patient.
[0142] The following illustrative, non-limiting examples are presented to aid in understanding the present invention.
[0143] Synthesis of Compounds of the Invention Unless otherwise stated, reagents and substrates were purchased from commercial suppliers (Cymit Quimica SL and Sigma-Aldrich). Thin-layer chromatography (TLC) analysis was performed on silica gel 60 F254 with aluminum plates and visualized with a UV lamp. Flash chromatography was performed on a column of silica gel 60 (230-400 mesh). MS analysis was performed using electrospray ionization (ESI) mode at 30 eV. 1 The H NMR spectrum is 1 H NMR was recorded at 400 or 500 MHz using CDCl3 or dimethylsulfoxide (DMSO) as solvents, and purity was determined by HPLC using a reversed stationary phase.
[0144] A) Examples of synthesis according to method A of the present invention Compounds of formula (I) were synthesized by applying the following synthetic protocol. [ka]
[0145] To a solution of the corresponding alkaryl compound derivative (15.6 mmol) in acetonitrile, N-bromosuccinimide (15.6 mmol, 2.37 g) and azobisisobutyronitrile (AIBN) (1.56 mmol, 0.256 g) were added. The reaction mixture was refluxed for 2 h, and azobisisobutyronitrile (0.78 mmol, 0.128 g) was added. After refluxing for 1 h, the mixture was stirred at room temperature for 16 h. The solvent was then evaporated under reduced pressure, and the crude material thus obtained was purified by flash chromatography (silica gel, ethyl acetate / hexane) to give the desired bromide compound. [ka]
[0146] To a solution of the corresponding bromide compound (1 mmol) in N,N-dimethylformamide (DMF) at 0° C. was added NaH (60% in mineral oil, 1.6 mmol, 0.062 g) or Na2CO3 (2.3 mmol, 0.244 g). After 30 min, the corresponding heterocyclic amine was added. The reaction was monitored by thin layer chromatography (TLC). Upon completion of the reaction, NH4Cl (saturated aqueous solution) was added and the product was extracted with ethyl acetate. The combined organic layers were dried over Na2SO4, filtered and concentrated. The residue was purified by flash chromatography (silica gel, ethyl acetate / hexane or MeOH / CH2Cl2). [ka]
[0147] To a solution of the corresponding nitrile compound (1.0 mmol) in N,N-dimethylformamide at room temperature, NaN3 (4.7 mmol, 0.305 g), NH4Cl (4.7 mmol, 0.251 g) and LiCl (1.7 mmol, 0.071 g) were added sequentially. The reaction mixture was stirred at 100° C. and monitored by TLC until the reaction was complete. The crude reaction mixture was used as is in the next step. [ka]
[0148] Difluoroacetic anhydride (DFAA) (20.0 mmol, 2.5 ml) was added to the crude reaction product obtained in the previous step at room temperature. The reaction mixture was stirred at 60° C. (when one or two of W, X, Y or Z were N) or 100° C. (when W, X, Y and Z were CH, respectively). The progress of the reaction was monitored by HPLC-MS. After completion of the reaction, water was added and the solution was extracted with ethyl acetate. The combined organic fractions were washed with water and brine, dried over Na2SO4 and evaporated under reduced pressure. The crude material thus obtained was purified by flash chromatography (silica gel, ethyl acetate / hexane) to give the desired product in high purity (>90%).
[0149] Representative examples prepared using this protocol were as follows: Example 1: 2-(4-((1H-indol-1-yl)methyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole [ka] Orange solid; 1 H NMR (δ ppm, 400 MHz, DMSO-d6) 8.02 (d, J = 8.3 Hz, 1H), 7.81 - 7.77 (m, 1H), 7.61 - 7.53 (m, 3H), 7.45 - 7.39 (m, 2H), 7.31 (d, J = 8.1 MS (ESI, m / z): 326.28 [M+1] + .
[0150] Example 2: 2-(4-((1H-pyrrolo[3,2-b]pyridin-1-yl)methyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole [ka] white solid; 1 H NMR (δ ppm, 400 MHz, DMSO-d6) 8.35 (dd, J = 4.7, 1.3 Hz, 1H), 8.03 (d, J = 8.3 Hz, 2H), 7.91 - 7.86 (m, 2H), 7.54 (t, J = 51.4 Hz, 1H), 7.43 (d, J = 8.2 Hz, 2H), 7.12 (dd, J = 8.3, 4.6 Hz, 1H), 6.66 (d, J = 3.3 Hz, 1H), 5.62 (s, 2H); MS (ESI, m / z): 327.08 [M+1] + .
[0151] Example 3: 2-(4-((1H-pyrrolo[3,2-c]pyridin-1-yl)methyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole [ka] white solid;1 H NMR (δ ppm, 400 MHz, DMSO-d6) 8.99 (s, 1H), 8.28 (d, J = 6.0 Hz, 1H), 8.04 (d, J = 8.3 Hz, 2H), 7.79 (d, J = 3.3 Hz, 1H), 7.71 (d, J = 6.0 Hz, 1H), 7.55 (t, J = 51.3 Hz, 1H), 7.45 (d, J = 8.1 Hz, 2H), 6.83 (d, J = 3.2 Hz, 1H), 5.68 (s, 2H); MS (ESI, m / z): 327.08 [M+1] + .
[0152] Intermediates: 4-((1H-Pyrrolo[3,2-c]pyridin-1-yl)methyl)benzonitrile
change
[0153] 1-(4-(1H-tetrazol-5-yl)benzyl)-1H-pyrrolo[3,2-c]pyridine
change
[0154] Example 4: 2-(4-((1H-pyrrolo[2,3-b]pyridin-1-yl)methyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole
change
[0155] Example 5: 1-(1-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1H-indol-3-yl)-2,2-difluoroethanone
change
[0156] Example 6: 2-(4-((1H-indazol-1-yl)methyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole
change
[0157] Example 7: 2-(4-((2H-indazol-2-yl)methyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole
change
[0158] Example 8: 2-(4-((1H-benzo[d]imidazol-1-yl)methyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole
change
[0159] Example 9: 1-(5,6-dichloro-1-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1H-benzo[d]imidazol-2-yl)-2,2-difluoroethanone
change
[0160] Example 10: 2-(4-((5,6-dichloro-1H-benzo[d]imidazol-1-yl)methyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole
change
[0161] Example 11: 2-(4-((1H-benzo[d][1,2,3]triazol-1-yl)methyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole [ka] white solid; 1 H NMR (δ ppm, 400 MHz, DMSO-d6) 8.10 (d, J = 8.4 Hz, 1H), 8.08 - 8.04 (m, 2H), 7.89 (d, J = 8.4 Hz, 1H), 7.54 (t, J = 51.4 Hz, 1H), 7.59 - 7.53 (m, 3H), 7.46 - 7.42 (m, 1H), 6.15 (s, 2H); MS (ESI, m / z): 328.24 [M+1] + .
[0162] Example 12 Example 12 was tested in biological assays as a mixture of its three triazole positional isomers, namely, 2-(difluoromethyl)-5-(4-((5-methyl-1H-benzo[d][1,2,3]triazol-1-yl)methyl)phenyl)-1,3,4-oxadiazole, 2-(difluoromethyl)-5-(4-((6-methyl-1H-benzo[d][1,2,3]triazol-1-yl)methyl)phenyl)-1,3,4-oxadiazole, and 2-(difluoromethyl)-5-(4-((5-methyl-2H-benzo[d][1,2,3]triazol-2-yl)methyl)phenyl)-1,3,4-oxadiazole. These three positional isomers can be separated by methods standard in the art, such as by silica column chromatography, but are represented here as a mixture since this is how they were tested in the biological assays referenced below. [ka] White solid; as a mixture of three regioisomers (distribution 1:1:1); MS (ESI, m / z): 342.25 [M+1] + .
[0163] Example 13: 2-(4-((6-chloro-1H-benzo[d][1,2,3]triazol-1-yl)methyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole [ka] white solid; 1 H NMR (δ ppm, 400 MHz, DMSO-d6) 8.17 (d, J = 1.8 Hz, 1H), 8.14 (d, J = 8.8 Hz, 1H), 8.09 - 8.05 (m, 2H), 7.59 - 7.55 (m, 2H), 7.54 (t, J = 51.4 Hz, 1H), 7.47 (dd, J = 8.8, 1.9 Hz, 1H), 6.12 (s, 2H), regiochemistry confirmed by nOe enhancement between the protons at 6.12 ppm and 8.17 ppm; MS (ESI, m / z): 362.18 and 364.21 [M+1] + .
[0164] Example 14: 1-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)naphthalen-2(1H)-one [ka] white solid; 1 H NMR (δ ppm, 400 MHz, DMSO-d6) 8.05 (d, J = 10.1 Hz, 1H), 8.03 (d, J = 8.7 Hz, 2H), 7.79 (dd, J = 7.8, 1.5 Hz, 1H), 7.54 (t, J = 51.4 Hz, 1H), 7.53 - 7.50 (m, 1H), 7.45 (d, J = 8.2 Hz, 2H), 7.39 (d, J = 8.6 Hz, 1H), 7.27 (t, J = 7.4 Hz, 1H), 6.77 (d, J = 9.5 Hz, 1H), 5.65 (s, 2H).; MS (ESI, m / z): 354.30 [M+1] + .
[0165] Example 15: 1-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-3,3-dimethylindolin-2-one [ka] White solid; 1 H NMR (δ ppm, 400 MHz, DMSO-d6) 8.03 (d, J = 8.3 Hz, 2H), 7.53 (t, J = 53.6 Hz, 1H), 7.52 (d, J = 8.3 Hz, 2H), 7.39 (dd, J = 7.6, 1.5 Hz, 1H), 7.18 (td, J = 7.7, 1.3 Hz, 1H), 7.04 (td, J = 7.5, 1.0 Hz, 1H), 6.91 (d, J = 7.8 Hz, 1H), 5.02 (s, 2H), 1.35 (s, 6H); MS (ESI, m / z): 370.27 [M+1] + .
[0166] Example 16: 2-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)isoindoline-1,3-dione
change
[0167] Example 17: 2-(difluoromethyl)-5-(4-((5-phenyl-1H-tetrazol-1-yl)methyl)phenyl)-1,3,4-oxadiazole
change
[0168] Example 18: 1-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-4-phenyl-1H-1,2,4-triazole-5(4H) -オン
change
[0169] Example 19: 1'-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)spiro[cyclohexane-1,3'-indolin]-2'-one
change
[0170] Example 20: 2-(4-(1-(1H-benzo[d]imidazol-1-yl)ethyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole
change
[0171] Example 21: 2-(6-((1H-benzo[d][1,2,3]triazol-1-yl)methyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole
change
[0172] Example 22: 2-(6-((5,6-dichloro-1H-benzo[d]imidazol-1-yl)methyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole
change
[0173] Example 23: 2-(6-((3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole [ka] white solid; 1 H NMR (δ ppm, 400 MHz, DMSO-d6) 9.09 (d, J = 2.2 Hz, 1H), 8.76 (dd, J = 4.5, 1.4 Hz, 1H), 8.65 (dd, J = 8.3, 1.4 Hz, 1H), 8.47 (dd, J = 8.2, 2.3 Hz, 1H), 7.65 (d, J = 8.2 Hz, 1H), 7.57 - 7.53 (m, 1H), 7.57 (t, J = 51.1 Hz, 1H), 6.25 (s, 2H), regiochemistry confirmed only by nOe enhancement between the protons at 6.25 ppm and 7.65 ppm; MS (ESI, m / z): 330.20 [M+1] + .
[0174] Example 24: 2-(6-((5,6-dichloro-1H-benzo[d][1,2,3]triazol-1-yl)methyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole [ka] white solid; 1H NMR (δ ppm, 400 MHz, DMSO-d6) 9.11 (d, J = 2.2 Hz, 1H), 8.55 (s, 1H), 8.48 (dd, J = 8.2, 2.3 Hz, 1H), 8.40 (s, 1H), 7.65 (d, J = 8.2 Hz, 1H), 7.58 (t, J = 51.2 Hz, 1H), 6.29 (s, 2H), regiochemistry confirmed by nOe enhancement between the protons at 6.29 ppm and 8.40 ppm; MS (ESI, m / z): 397.20 and 399.16 [M+1] + .
[0175] Example 25: 2-(6-((5,6-dichloro-2H-benzo[d][1,2,3]triazol-2-yl)methyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole [ka] white solid; 1 H NMR (δ ppm, 400 MHz, DMSO-d6) 9.16 (d, J = 2.2 Hz, 1H), 8.50 (dd, J = 8.1, 2.3 Hz, 1H), 8.45 (s, 2H), 7.65 (d, J = 8.3 Hz, 1H), 7.59 (t, J = 51.2 Hz, 1H), 6.30 (s, 2H), regiochemistry confirmed only by nOe enhancement between the protons at 6.30 ppm and 7.65 ppm; MS (ESI, m / z): 397.22 and 399.20 [M+1] + .
[0176] Example 26: 2-(difluoromethyl)-5-(6-((4-phenyl-1H-imidazol-1-yl)methyl)pyridin-3-yl)-1,3,4-oxadiazole [ka] white solid; 1H NMR (δ ppm, 400 MHz, CDCl3-d) 9.35 (d, J = 2.2 Hz, 1H), 8.40 (dd, J = 8.2, 2.3 Hz, 1H), 7.84 - 7.78 (m, 2H), 7.75 (s, 1H), 7.40 (t, J = 7.6 Hz, 2H), 7.30 - 7.27 (m, 1H), 7.33 (s, 1H), 7.23 (d, J = 8.2 Hz, 1H), 6.96 (t, J = 51.6 Hz, 1H), 5.41 (s, 2H), The regiochemistry was confirmed by nOe enhancement between the protons at 5.41 ppm and 7.23 ppm, 7.33 ppm, and 7.75 ppm; MS (ESI, m / z): 354.26 [M+1] + .
[0177] Example 58: 2-(6-((5,6-dichloro-2-(trifluoromethyl)-1H-benzo[d]imidazol-1-yl)methyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole [ka] white solid; 1 H NMR (δ ppm, 400 MHz, CDCl3-d) 9.05 - 9.03 (m, 1H), 8.48 (dd, J = 8.2, 2.2 Hz, 1H), 8.30 (s, 1H), 8.27 (s, 1H), 7.67 (d, J = 8.3 Hz, 1H), 7.57 (t, J = 51.2 Hz, 1H), 6.01 (s, 2H); MS (ESI, m / z): 464.19 and 466.19 [M+1] + .
[0178] Example 59: 2-(difluoromethyl)-5-(6-((5,6-dimethyl-1H-benzo[d][1,2,3]triazol-1-yl)methyl)pyridin-3-yl)-1,3,4-oxadiazole [ka] white solid; 1H NMR (δ ppm, 400 MHz, CDCl3-d) 9.14 (d, J = 2.3 Hz, 1H), 8.45 (dd, J = 8.2, 2.3 Hz, 1H), 7.84 (s, 1H), 7.59 (s, 1H), 7.57 (t, J = 51.3 Hz, 1H), 7.46 (d, J = 8.4 Hz, 1H), 6.18 (s, 2H), 2.37 (d, J = 4.3 Hz, 6H); MS (ESI, m / z): 357.24 [M+1] + .
[0179] Example 60: 2-(6-((5,6-dichloro-2-methyl-1H-benzo[d]imidazol-1-yl)methyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole
change
[0180] Example 61: 2-(difluoromethyl)-5-(6-((5,6-dimethyl-1H-benzo[d]imidazol-1-yl)methyl)pyridin-3-yl)-1,3,4-oxadiazole
change
[0181] Example 62: 2-(6-((6-bromo-1H-benzo[d]imidazol-1-yl)methyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole, and Example 63: 2-(6-((5-bromo-1H-benzo[d]imidazol-1-yl)methyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole [ka] Two enriched fractions were obtained: Fraction 1: yellow oil; mixture of two regioisomers (distribution first eluting compound: second eluting compound 37:63); MS (ESI, m / z): 406.17 and 408.17 [M+1] + The first eluting compound and 406.17 and 408.17 [M+1] + The second eluting compound.
[0182] Fraction 2: yellow oil; mixture of two regioisomers (distribution first eluting compound: second eluting compound 62:38); MS (ESI, m / z): 406.17 and 408.17 [M+1] + The first eluting compound and 406.17 and 408.17 [M+1] + 2 nd The compound that eluted second.
[0183] Examples 57 and 58 can be separated by methods standard in the art, such as by silica column chromatography, but are represented here as their concentrated mixtures since this is how they were tested in the biological assays referenced below.
[0184] Example 64: 2-(6-((5-bromo-1H-benzo[d][1,2,3]triazol-1-yl)methyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole [ka] yellow oil; 1 H NMR (δ ppm, 400 MHz, CDCl3-d) 9.33 (d, J = 2.0 Hz, 1H), 8.38 (dd, J = 8.2, 2.2 Hz, 1H), 8.28 (dd, J = 1.7, 0.7 Hz, 1H), 7.60 (dd, J = 8.8, 1.6 Hz, 1H), 7.49 (dd, J = 8.7, 0.7 Hz, 1H), 7.33 (d, J = 8.2 Hz, 1H), 6.95 (t, J = 51.6 Hz, 1H), 6.07 (s, 2H), regiochemistry confirmed by nOe enhancement between the proton at 6.07 ppm and the protons at 7.33 ppm and 7.49 ppm; MS (ESI, m / z): 407.18 and 409.18 [M+1] + .
[0185] Example 65: 2-(6-((6-bromo-1H-benzo[d][1,2,3]triazol-1-yl)methyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole [ka] yellow oil; 1 H NMR (δ ppm, 400 MHz, CDCl3-d) 9.35 (s, 1H), 8.39 (dd, J = 8.2, 2.1 Hz, 1H), 7.99 (d, J = 8.8 Hz, 1H), 7.79 (d, J = 1.8 Hz, 1H), 7.52 (dd, J = 8.8, 1.6 Hz, 1H), 7.34 (d, J = 8.2 Hz, 1H), 6.95 (t, J = 51.6 Hz, 1H), 6.05 (s, 2H), regiochemistry confirmed by nOe enhancement between the protons and the protons at 7.34 ppm and 7.79 ppm; MS (ESI, m / z): 407.18 and 409.18 [M+1] + .
[0186] Example 66: 2-(6-((5-bromo-2H-benzo[d][1,2,3]triazol-2-yl)methyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole [ka] yellow oil; 1 H NMR (δ ppm, 400 MHz, CDCl3-d) 9.34 (d, J = 2.1 Hz, 1H), 8.40 (dd, J = 8.2, 2.2 Hz, 1H), 8.11 (d, J = 1.7 Hz, 1H), 7.81 (dd, J = 9.0, 0.8 Hz, 1H), 7.53 (dd, J = 9.1, 1.7 Hz, 1H), 7.31 (d, J = 8.2 Hz, 1H), 6.95 (t, J = 51.7 Hz, 1H), 6.15 (s, 2H), regiochemistry confirmed only by nOe enhancement between the protons at 6.15 ppm and 7.31 ppm; MS (ESI, m / z): 407.18 and 409.18 [M+1] + .
[0187] B) Examples of synthesis according to method B of the present invention Compounds of formula (I) were synthesized by applying the following synthetic protocol. [ka] To a solution of the corresponding alkaryl compound (15.6 mmol) in acetonitrile, N-bromosuccinimide (NBS) (15.6 mmol, 2.37 g) and azobisisobutyronitrile (AIBN) (1.56 mmol, 0.256 g) were added. The reaction mixture was refluxed for 2 h, and azobisisobutyronitrile (0.78 mmol, 0.128 g) was added again. After refluxing for 1 h, the mixture was stirred at room temperature for 16 h. The solvent was then evaporated under reduced pressure, and the crude material thus obtained was purified by flash chromatography (silica gel, ethyl acetate / hexane) to give the bromide compound.
[0188] Where W, X, Y and Z are all CH [ka] To a solution of the corresponding bromide compound (1.0 mmol) in N,N-dimethylformamide (DMF) at room temperature, NaN3 (4.7 mmol, 0.305 g), NH4Cl (4.7 mmol, 0.251 g) and LiCl (1.7 mmol, 0.071 g) were added successively. The reaction mixture was stirred at 100° C. and monitored by TLC until the reaction was complete. Ethyl acetate was then added and the organic layer was washed with water, dried over sodium sulfate, filtered and evaporated under reduced pressure. The crude material thus obtained was used without further purification.
[0189] [ka] To a solution of the corresponding alkyne (0.5 mmol), azide compound (0.5 mmol) and CuI (0.22 mmol, 0.041 g) in N,N-dimethylformamide at room temperature was added N,N-diisopropylethylamine (DIPEA) (2.8 mmol, 0.5 ml). The reaction mixture was stirred and monitored by HPLC-MS. Upon completion of the reaction, ethyl acetate was added. The organic layer was then washed with NH3 / H2O (x2) and brine, dried over Na2SO4, filtered and evaporated under reduced pressure. The crude material thus obtained was purified by flash chromatography (silica gel, ethyl acetate / hexane) to give the desired product.
[0190] When one or two of W, X, Y or Z are N (pyridine is an example) [ka] To a solution of the corresponding bromide compound (1.0 mmol) in N,N-dimethylformamide was added NaN3. The reaction mixture was stirred at room temperature for 5 hours. Ethyl acetate was then added and the organic layer was washed with water and brine, dried over sodium sulfate, filtered and evaporated under reduced pressure. The crude material thus obtained was used without further purification. [ka]
[0191] To a solution of the corresponding alkyne (0.5 mmol), azide compound (0.5 mmol) and CuI (0.22 mmol, 0.041 g) in N,N-dimethylformamide at room temperature was added N,N-diisopropylethylamine (DIPEA) (2.8 mmol, 0.5 ml). The reaction mixture was stirred and monitored by HPLC-MS. Upon completion of the reaction, ethyl acetate was added. The organic layer was then washed with NH3 / H2O (x2) and brine, dried over Na2SO4, filtered and evaporated under reduced pressure. The crude material thus obtained was purified by flash chromatography (silica gel, ethyl acetate / hexane) to give the desired product. [ka]
[0192] To a solution of the corresponding nitrile compound (1.0 mmol) in N,N-dimethylformamide at room temperature, NaN3 (4.7 mmol, 0.305 g), NH4Cl (4.7 mmol, 0.251 g) and LiCl (1.7 mmol, 0.071 g) were added sequentially. The reaction mixture was stirred at 100° C. and monitored by TLC until the reaction was complete. The crude material thus obtained was used without further purification. [ka]
[0193] Difluoroacetic anhydride (DFAA) (20.0 mmol, 2.5 ml) was added to the crude reaction product obtained in the previous step at room temperature. The reaction mixture was stirred at 60° C. (when one or two of W, X, Y or Z were N) or 100° C. (when W, X, Y and Z were CH, respectively). The progress of the reaction was monitored by HPLC-MS. After completion of the reaction, water was added and the solution was extracted with ethyl acetate. The combined organic fractions were washed with water and brine, dried over Na2SO4 and evaporated under reduced pressure. The crude material thus obtained was purified by flash chromatography (silica gel, ethyl acetate / hexane) to give the desired product in high purity (>90%).
[0194] Representative examples prepared using this protocol were as follows: Example 27: 2-(difluoromethyl)-5-(4-((4-phenyl-1H-1,2,3-triazol-1-yl)methyl)phenyl)-1,3,4-oxadiazole [ka] white solid; 1 H NMR (δ ppm, 400 MHz, DMSO-d6) 8.72 (s, 1H), 8.10 (d, J = 8.3 Hz, 2H), 7.87 (d, J = 7.1 Hz, 2H), 7.58 (d, J = 8.2 Hz, 2H), 7.56 (t, J = 51.3 MS (ESI, m / z): 354.30 [M+1] + .
[0195] Example 28: 1-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-1H-1,2,3-triazole-4-carboxylate methyl [ka] white solid; 1H NMR (δ ppm, 400 MHz, DMSO-d6) 8.96 (s, 1H), 7.88 (d, J = 8.3 Hz, 2H), 7.56 (t, J = 52.6 Hz, 1H), 7.50 (d, J = 8.3 Hz, 2H), 5.80 (s, 2H), 3.84 (s, 3H); MS (ESI, m / z): 336.26 [M+1] + .
[0196] Example 29: 2-(4-((4-(4-chlorophenyl)-1H-1,2,3-triazol-1-yl)methyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole
change
[0197] Example 30: 2-(difluoromethyl)-5-(4-((4-(4-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-1-yl)methyl)phenyl)-1,3,4-oxadiazole
change
[0198] Example 31: 2-(4-((4-(tert-ブチル)-1H-1,2,3-トリアゾール-1-イル)メチル)フェニル)-5-(ジフルオロメチル)-1,3,4-オキサジアゾール
change
[0199] Example 32: 2-(4-((4-cyclohexyl-1H-1,2,3-triazol-1-yl)methyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole
change
[0200] Example 33: 2-(difluoromethyl)-5-(4-((4-(pyridin-4-yl)-1H-1,2,3-triazol-1-yl)methyl)phenyl)-1,3,4-oxadiazole
change
[0201] Example 34: 2-(difluoromethyl)-5-(4-((4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)methyl)phenyl)-1,3,4-oxadiazole
change
[0202] Example 35: 2-(difluoromethyl)-5-(4-((4-(thiophen-3-yl)-1H-1,2,3-triazol-1-yl)methyl)phenyl)-1,3,4-oxadiazole
change
[0203] Example 36: 2-(difluoromethyl)-5-(4-((4-(thiophen-2-yl)-1H-1,2,3-triazol-1-yl)methyl)phenyl)-1,3,4-oxadiazole
change
[0204] Example 37: 2-(difluoromethyl)-5-(4-(1-(4-phenyl-1H-1,2,3-triazol-1-yl)ethyl)phenyl)-1,3,4-oxadiazole
change
[0205] Example 38: 2-(difluoromethyl)-5-(4-((4,5-diphenyl-1H-1,2,3-triazol-1-yl)methyl)phenyl)-1,3,4-oxadiazole
change
[0206] Example 39: 2-(difluoromethyl)-5-(4-((5-methyl-4-phenyl-1H-1,2,3-triazol-1-yl)methyl)phenyl)-1,3,4-oxadiazole
change
[0207] Example 40: 2-(difluoromethyl)-5-(4-((4-methyl-5-phenyl-1H-1,2,3-triazol-1-yl)methyl)phenyl)-1,3,4-oxadiazole [ka] white solid; 1 H NMR (δ ppm, 400 MHz, CDCl3-d) 8.06 - 8.02 (m, 2H), 7.49 - 7.45 (m, 3H), 7.22 (d, J = 8.2 Hz, 2H), 7.16 (dd, J = 7.4, 2.2 Hz, 2H), 6.93 (t, J = 51.7 Hz, 1H), 5.55 (s, 2H), 2.35 (s, 3H); MS (ESI, m / z): 368.27 [M+1] + .
[0208] Example 41: 2-(difluoromethyl)-5-(6-((4-phenyl-1H-1,2,3-triazol-1-yl)methyl)pyridin-3-yl)-1,3,4-oxadiazole [ka] white solid; 1H NMR (δ ppm, 400 MHz, DMSO-d6) 9.21 (d, J = 2.2 Hz, 1H), 8.74 (s, 1H), 8.50 (dd, J = 8.2, 2.3 Hz, 1H), 7.89 (dd, J = 8.3, 1.3 Hz, 1H), 7.59 (t, J = 51.4 Hz, 1H), 7.58 (d, J = 8.5 Hz, 2H), 7.47 (t, J = 7.6 Hz, 2H), 7.36 (t, J = 7.4 Hz, 1H), 5.94 (s, 2H); MS (ESI, m / z): 355.25 [M+1] + .
[0209] Intermediates: 6-(Bromomethyl)nicotinonitrile [ka] MS (ESI, m / z): 196.99 [M+1] + .
[0210] 6-(azidomethyl)nicotinonitrile [ka] MS (ESI, m / z): 160.02 [M+1] + .
[0211] 6-((4-phenyl-1H-1,2,3-triazol-1-yl)methyl)nicotinonitrile, having the following structure: [ka] MS (ESI, m / z): 262.20 [M+1] + .
[0212] 2-((4-phenyl-1H-1,2,3-triazol-1-yl)methyl)-5-(1H-tetrazol-5-yl)pyridine [ka] MS (ESI, m / z): 305.23 [M+1] + .
[0213] Example 42: 2-(difluoromethyl)-5-(5-((4-phenyl-1H-1,2,3-triazol-1-yl)methyl)pyridin-2-yl)-1,3,4-oxadiazole
change
[0214] Example 43: 2-(6-((4-(4-chlorophenyl)-1H-1,2,3-triazol-1-yl)methyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole
change
[0215] Example 44: 2-(6-((4-(2-chlorophenyl)-1H-1,2,3-triazol-1-yl)methyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole
change
[0216] Example 45: 2-(6-((4-(3-chlorophenyl)-1H-1,2,3-triazol-1-yl)methyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole
change
[0217] Example 46: 2-(6-((4-(3,4-dichlorophenyl)-1H-1,2,3-triazol-1-yl)methyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole
change
[0218] Example 47: 2-(6-((4-(3,5-dichlorophenyl)-1H-1,2,3-triazol-1-yl)methyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole
change
[0219] Example 48: 2-(difluoromethyl)-5-(6-((4-(2-fluorophenyl)-1H-1,2,3-triazol-1-yl)methyl)pyridin-3-yl)-1,3,4-oxadiazole
change
[0220] Example 49: 2-(difluoromethyl)-5-(6-((4-(2,6-difluorophenyl)-1H-1,2,3-triazol-1-yl)methyl)pyridin-3-yl)-1,3,4-oxadiazole
change
[0221] Example 50: 2-(6-((4-(3-chlorophenyl)-1H-1,2,3-triazol-1-yl)methyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole
change
[0222] Example 56: 2-(difluoromethyl)-5-(6-((4-(3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)methyl)pyridin-3-yl)-1,3,4-oxadiazole
change
[0223] Example 57: 2-(difluoromethyl)-5-(6-((4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)methyl)pyridin-3-yl)-1,3,4-oxadiazole
change
[0224] C) Examples of synthesis according to method C of the present invention Compounds of formula (I) were synthesized by applying the following synthetic protocol. [ka] CuI (2.5 mmol, 0.500 g) was dissolved in ammonium hydroxide. The corresponding arylacetylene was added dropwise with stirring. After 15 min, the resulting yellow precipitate was filtered and washed with water, EtOH, and Et2O.
[0225] When W, X, Y and Z are all CH [ka] To a solution of the corresponding copper(I) aryl acetylenide (0.5 mmol) and the corresponding azide compound (synthesized as described for method B; 0.6 mmol) in CHCl (1 ml) was added N-chlorosuccinimide (0.6 mmol, 0.080 g). The mixture was stirred at room temperature and monitored by HPLC-MS. Upon completion of the reaction, dichloromethane was evaporated under reduced pressure and the crude material thus obtained was purified by flash chromatography (silica gel, ethyl acetate / hexane) to give the desired product.
[0226] When one or two of W, X, Y or Z are N (pyridine is an example) [ka] To a solution of the corresponding copper(I) aryl acetylenide (0.5 mmol) and the corresponding azide derivative (synthesized as described for method B; 0.6 mmol) in CHCl (1 ml) was added N-chlorosuccinimide (0.6 mmol, 0.080 g). The mixture was stirred at room temperature and monitored by HPLC-MS. Upon completion of the reaction, dichloromethane was evaporated under reduced pressure and the crude material thus obtained was purified by flash chromatography (silica gel, ethyl acetate / hexane) to give the desired product. [ka]
[0227] To a solution of the corresponding nitrile derivative (1.0 mmol) in N,N-dimethylformamide at room temperature, NaN3 (4.7 mmol, 0.305 g), NH4Cl (4.7 mmol, 0.251 g) and LiCl (1.7 mmol, 0.071 g) were added sequentially. The reaction mixture was stirred at 100° C. and monitored by TLC until the reaction was complete. The crude material thus obtained was used without further purification. [ka]
[0228] To the crude reaction product obtained in the previous step, DFAA (20.0 mmol, 2.5 ml) was added at room temperature. The reaction mixture was stirred at 60° C. (for W=N) or 100° C. (for W=C). The progress of the reaction was monitored by HPLC-MS. After completion of the reaction, water was added and the solution was extracted with ethyl acetate. The combined organic fractions were washed with water and brine, dried over Na2SO4, and evaporated under reduced pressure. The crude material thus obtained was purified by flash chromatography (silica gel, ethyl acetate / hexane) to give the desired product in high purity (>90%).
[0229] Representative examples prepared using this protocol were as follows:
[0230] Example 51: 2-(4-((5-chloro-4-phenyl-1H-1,2,3-triazol-1-yl)methyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole
change
[0231] Intermediates: (Phenylethynyl)copper
change
[0232] (5-(4-(azidomethyl)phenyl)-1H-tetrazole
change
[0233] 5-(4-((5-chloro-4-phenyl-1H-1,2,3-triazol-1-yl)methyl)phenyl)-1H-tetrazole
change
[0234] Example 52: 2-(6-((5-chloro-4-phenyl-1H-1,2,3-triazol-1-yl)methyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole having the following structural formula:
change
[0235] Example 53: 2-(6-((5-chloro-4-(2-chlorophenyl)-1H-1,2,3-triazol-1-yl)methyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole
change
[0236] Example 54: 2-(6-((5-chloro-4-(3-chlorophenyl)-1H-1,2,3-triazol-1-yl)methyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole
change
[0237] Example 67: Preparation of 2-(6-((5-chloro-4-(2-fluorophenyl)-1H-1,2,3-triazol-1-yl)methyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole having the following structural formula: [ka] This compound was prepared following the procedure described in Method C. Yellow oil; 1 H NMR (δ ppm, 400 MHz, CDCl3-d) 9.37(s, 1H), 8.46 (d, J = 8.1 Hz, 1H), 7.76 (td, J = 7.5, 1.8 Hz, 1H), 7.47 (tdd, J = 7.3, 6.1, 1.6 Hz, 1H), 7.33 - 7.27 (m, 2H), 7.23 (ddd, J = 9.7, 8.3, 1.1 Hz, 1H), 6.97 (t, J = 51.6 Hz, 1H), 5.88 (s, 2H); MS (ESI, m / z): 407.22 and 409.22 [M+1] + .
[0238] The compounds obtained by any of the above methods can be further converted into other compounds of the invention. Representative examples are shown below.
[0239] Example 55: 2-(6-(chloro(4-phenyl-1H-1,2,3-triazol-1-yl)methyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole [ka] To a solution of Example 39 (0.05 mmol) in N,N-dimethylformamide (0.3 ml) was added N-chlorosuccinimide (0.08 mmol, 0.015 g). The resulting mixture was refluxed for 16 h. The crude reaction solution was then evaporated to dryness under reduced pressure and purified by flash chromatography (silica gel, ethyl acetate / hexanes) to give the desired product. yellow oil; 1 H NMR (δ ppm, 400 MHz, CDCl3-d) 9.43 (d, J = 2.2 Hz, 1H), 8.58 (dd, J = 8.2, 2.2 Hz, 1H), 8.42 (s, 1H), 7.94 - 7.88 (m, 3H), 7.69 (s, 1H), 7.48 (dd, J = 8.2, 6.7 Hz, 2H), 7.44 - 7.37 (m, 1H), 6.99 (t, J = 51.6 Hz, 1H); MS (ESI, m / z): 389.25 and 391.25 [M+1] + .
[0240] Biological activity of the compounds of the present invention All enzymatic reactions were carried out in duplicate for 17 hours at room temperature in 50 μL mixtures containing HDAC assay buffer (50 mM Tris-HCl, pH 7.4, 137 mM NaCl, 2.7 mM KCl, 0.05% Tween 20, 5 μg BSA), HDAC substrate, HDAC enzyme, and test compound. Compound dilutions were prepared at 100 times the final compound concentration with 100% DMSO, and 300 nL of the dilution was added to 30 μL reactions by an Echo acoustic dispenser to achieve a final DMSO concentration of 1% in all reactions. After the enzymatic reaction, the reaction was stopped by adding 5 μl of a 10 μM solution of a known inhibitor. Fluorescence signals of substrate and product were measured by means of a microfluidic mobility assay on an EZ Reader II instrument. The percentage conversion of substrate to product was calculated by the instrument software based on the peak area.
[0241] The conversion percentage data was analyzed using computer software Graphpad Prism. The conversion (Ct) of each data set in the absence of compound was defined as 100% activity. The conversion (Cb) of each data set in the absence of HDAC was defined as 0% activity. The percent activity in the presence of each compound was calculated according to the following formula: % inhibition = (Ct-C) / (Ct-Cb) (C = conversion percentage in the presence of compound).
[0242] The % inhibition values for the range of compound concentrations were then plotted using nonlinear regression analysis of sigmoidal dose-response curves generated using the equation Y=B+(TB) / 1+10((LogEC50-X)×Hill slope), where Y=percent inhibition, B=minimal percent inhibition, T=maximal percent inhibition, X=log compound, and Hill slope=slope coefficient or Hill coefficient. IC 50 Values were determined by the concentration producing half-maximal percent activity.
[0243] hHDAC1 Inhibition Protocol: The assay buffer used for the inhibition hHDAC1 assay is Hepes 50 mM, KCl 100 mM, Tween 20 0.001%, BSA 0.01%; pH=7.4. Test compounds and HDAC1 (BPS Bioscience 50010) enzyme 5 nM were added to a 384-well microplate (Geriner 784209) and incubated at room temperature for 3 hours. Then, acetylated peptide A (Perkin Elmer CLS960006) 2 μM was added and incubated at room temperature for 1 hour. Finally, the reaction was stopped by adding LBH589 (Reaction Biology Corp EPI009B) 1.4 μM. The reaction was measured on a Caliper EzReader LabChip 3000 (Caliper, Hopkinton, MA) reader. Literature IC50 values of control compounds to validate the assay: hHDAC1, LBH-589 (Reaction Biology Corp EPI009B) IC50 1nM, J Med Chem 2016, 59, 1455-1470.
[0244] hHDAC2 Inhibition Protocol: The assay buffer used for the inhibition hHDAC2 assay is Hepes 50 mM, KCl 100 mM, Tween 20 0.001%, BSA 0.01%; pH=7.4. Test compounds and HDAC2 (BPS Bioscience 50002) enzyme 12 nM were added to a 384-well microplate (Geriner 784209) and incubated at room temperature for 3 hours. Then, acetylated peptide A (Perkin Elmer CLS960006) 1 μM was added and incubated at room temperature for 1 hour. Finally, the reaction was stopped by adding LBH589 (Reaction Biology Corp EPI009B) 1.4 μM. The reaction was measured on a Caliper EzReader LabChip 3000 (Caliper, Hopkinton, MA) reader. hHDAC2, LBH-589 (Reaction Biology Corp EPI009B) IC50<3nM, Gale et al, Application note Perkin Elmer.
[0245] hHDAC3 Inhibition Protocol: The assay buffer used for the inhibition hHDAC3 assay is Hepes 50 mM, KCl 100 mM, Tween 20 0.001%, BSA 0.01%; pH=7.4. Test compounds and HDAC3 (BPS Bioscience 50003) enzyme 5 nM were added to a 384-well microplate (Geriner 784209) and incubated at room temperature for 3 hours. Then, acetylated peptide A (Perkin Elmer CLS960006) 2 μM was added and incubated at room temperature for 1 hour. Finally, the reaction was stopped by adding LBH589 (Reaction Biology Corp EPI009B) 1.4 μM. The reaction was measured on a Caliper EzReader LabChip 3000 (Caliper, Hopkinton, MA) reader. Literature IC50 values of control compounds to validate the assay: hHDAC3, LBH-589 (Reaction Biology Corp EPI009B) IC50 2nM, Cancer Lett 2009;280:233-241.
[0246] hHDAC4 Inhibition Protocol: The assay buffer used for the inhibition hHDAC4 assay is Hepes 50 mM, KCl 100 mM, Tween 20 0.001%, BSA 0.01%; pH=7.4. Test compounds and HDAC4 (BPS Bioscience 50004) enzyme 0.5 nM were added to a 384-well microplate (Geriner 784209) and incubated for 5 min at room temperature. Then, acetylated peptide B (Perkin Elmer CLS960007) 1 μM was added and incubated for 1 h at room temperature. Finally, the reaction was stopped by adding LBH589 (Reaction Biology Corp EPI009B) 1.4 μM. The reaction was measured on a Caliper EzReader LabChip 3000 (Caliper, Hopkinton, MA) reader. Literature IC50 values of control compounds to validate the assay: hHDAC4, LBH-589 (Reaction Biology Corp EPI009B), IC50 65nM, Gale et al., Application note Perkin Elmer.
[0247] hHDAC5 Inhibition Protocol: The assay buffer used for the inhibition hHDAC5 assay is Hepes 50 mM, KCl 100 mM, Tween 20 0.001%, BSA 0.01%; pH=7.4. Test compounds and HDAC5 (BPS Bioscience 50005) enzyme 0.75 nM were added to a 384-well microplate (Geriner 784209) and incubated at room temperature for 5 min. Then, acetylated peptide B (Perkin Elmer CLS960007) 2 μM was added and incubated at room temperature for 1 h. Finally, the reaction was stopped by adding LBH589 (Reaction Biology Corp EPI009B) 1.4 μM. The reaction was measured on a Caliper EzReader LabChip 3000 (Caliper, Hopkinton, MA) reader. Literature IC50 values of control compounds to validate the assay: hHDAC5, LBH-589 (Reaction Biology Corp EPI009B), IC50 160nM, Nat. Chem. Biol. 6,238-243 (2010).
[0248] HDAC6 Inhibition Protocol: The assay buffer used for the inhibition hHDAC6 assay is Hepes 50 mM, KCl 100 mM, Tween 20 0.001%, BSA 0.01%; pH=7.4. Test compounds and hHDAC6 (BPS Bioscience 50006) enzyme 1.20 nM were added to a 384-well microplate (Greiner 784209) and incubated for 5 min at room temperature. Then, acetylated peptide A (Perkin Elmer CLS960006) 2 μM was added and incubated for 1 h at room temperature. Finally, the reaction was stopped by adding LBH589 (Reaction Biology Corp EPI009B) 1.4 μM. The reaction was measured on a Caliper EzReader LabChip 3000 (Caliper, Hopkinton, MA) reader. Literature IC50 values of control compounds to validate the assay: hHDAC6, LBH589 (Reaction Biology Corp EPI009B), IC50 2.0nM, Gale et al., Perkin Elmer Application note.
[0249] hHDAC7 Inhibition Protocol: The assay buffer used for the inhibition hHDAC7 assay is Hees 50 mM, KCl 100 mM, Tween 20 0.001%, BSA 0.01%; pH=7.4. Test compounds and HDAC7 (BPS Bioscience 50007) enzyme 5 nM were added to a 384-well microplate (Geriner 784209) and incubated at room temperature for 5 min. Then, acetylated peptide B (Perkin Elmer CLS960007) 2 μM was added and incubated at room temperature for 1 h. Finally, the reaction was stopped by adding LBH589 (Reaction Biology Corp EPI009B) 1.4 μM. The reaction was measured on a Caliper EzReader LabChip 3000 (Caliper, Hopkinton, MA) reader. Literature IC50 values of control compounds to validate the assay: Literature IC50 values of control compounds to validate the assay: hHDAC7, LBH-589 (Reaction Biology Corp EPI009B), IC50 760nM, Gale et al, Application note Perkin Elmer.
[0250] hHDAC8 Inhibition Protocol: The assay buffer used for the inhibition hHDAC8 assay is Hepes 50 mM, KCl 100 mM, Tween 20 0.001%, BSA 0.01%; pH=7.4. Test compounds and HDAC8 (BPS Bioscience 50008) enzyme 1 nM were added to a 384-well microplate (Geriner 784209) and incubated at room temperature for 5 min. Then, acetylated peptide B (Perkin Elmer CLS960007) 2 μM was added and incubated at room temperature for 1 h. Finally, the reaction was stopped by adding LBH589 (Reaction Biology Corp EPI009B) 1.4 μM. The reaction was measured on a Caliper EzReader LabChip 3000 (Caliper, Hopkinton, MA) reader. Literature IC50 values of control compounds to validate the assay: hHDAC8, trichostatin A (Reaction Biology Corp. EPI009F), IC50 90 nM, Bradner, JE et al. Nat. Chem. Biol. 6, 238-243 (2010).
[0251] hHDAC9 Inhibition Protocol: The assay buffer used for the inhibition hHDAC9 assay is Hepes 50 mM, KCl 100 mM, Tween 20 0.001%, BSA 0.01%; pH=7.4. Test compounds and HDAC9 (BPS Bioscience 50009) enzyme 2 nM were added to a 384-well microplate (Geriner 784209) and incubated at room temperature for 5 min. Then, acetylated peptide B (Perkin Elmer CLS960007) 2 μM was added and incubated at room temperature for 1 h. Finally, the reaction was stopped by adding LBH589 (Reaction Biology Corp EPI009B) 1.4 μM. The reaction was measured on a Caliper EzReader LabChip 3000 (Caliper, Hopkinton, MA) reader. Literature IC50 values of control compounds to validate the assay: hHDAC9, LBH-589 (Reaction Biology Corp EPI009B), IC50 390nM, Gale et al., Application note Perkin Elmer.
[0252] HDAC10 Inhibition Protocol: The assay buffer used for the inhibition hHDAC10 assay is Hepes 50 mM, KCl 100 mM, Tween 20 0.001%, BSA 0.01%; pH=7.4. Test compounds and hHDAC10 (BPS Bioscience 50010) enzyme 10 nM were added to a 384-well microplate (Geriner 784209) and incubated at room temperature for 60 min. Then, acetylated peptide A (Perkin Elmer CLS960006) 6 μM was added and incubated at room temperature for 24 h. Finally, the reaction was stopped by adding LBH589 (Reaction Biology Corp EPI009B) 1.4 μM. The reaction was measured on a Caliper EzReader LabChip 3000 (Caliper, Hopkinton, MA) reader. Literature IC50 values of control compounds to validate the assay: hHDAC10, SAHA (supplied by Quimatryx), IC50 456nM, Hanessian et al., ACS Med. Chem. Lett. 2010, 1, 2, 70-74.
[0253] Regarding Examples 1 to 67, the following HDAC6 inhibitory activity was observed.
[0254] [Table 2] TIFF0007593647000111.tif84142
[0255] In addition, Examples (Ex.) 1 to 67 showed a high degree of selectivity against other HDAC1 to 10 enzymes. Representative selectivities are shown in the table below. [Table 3]
Claims
1. A compound of formula (I) or a salt, solvate or stereoisomer thereof [Formula 1] [In the formula, one or two of W, X, Y or Z are N and the remaining ones of W, X, Y and Z are each CH; or each of W, X, Y and Z is CH; R 1 is H; unsubstituted or substituted alkyl; or halogen; and R 2 is an unsubstituted or substituted, aromatic or non-aromatic heterocyclic ring, said ring containing 1 to 4 nitrogen atoms, and R 2 One of these ring nitrogen atoms of the group forms a bond with the remainder of formula (I).
2. 2. The compound of claim 1, or a salt, solvate, or stereoisomer thereof, wherein X is N and the remainder of W, X, Y, and Z are each CH.
3. 2. The compound of claim 1, or a salt, solvate, or stereoisomer thereof, wherein each of W, X, Y, and Z is CH.
4. R 1 The compound according to any one of claims 1 to 3, or a salt, solvate or stereoisomer thereof, wherein
5. R 2 The compound according to any one of claims 1 to 4, or a salt, solvate or stereoisomer thereof, wherein is aromatic.
6. R 2 6. The compound of claim 5, or a salt, solvate, or stereoisomer thereof, wherein is a 5-membered monocyclic heteroaryl ring.
7. R 2 7. The compound of claim 6, or a salt, solvate, or stereoisomer thereof, wherein is a triazolyl or imidazolyl ring.
8. R 2 6. The compound of claim 5, or a salt, solvate, or stereoisomer thereof, wherein is a 9-membered bicyclic heteroaryl ring.
9. R 2 9. The compound of claim 8, or a salt, solvate, or stereoisomer thereof, wherein is a benzotriazolyl or benzimidazolyl ring.
10. the below described: [chemical 2] [ka] [ka] [ka] [ka] 2. The compound of claim 1, or a salt, solvate or stereoisomer thereof, selected from:
11. A process for the preparation of a compound of formula (I) as defined in any one of claims 1 to 10, or a salt, solvate or stereoisomer thereof, comprising the steps of: [C3] [In the formula, W, X, Y, Z, R 1 , R 2 is as defined in any one of claims 1 to 10. with difluoroacetic anhydride.
12. A pharmaceutical composition comprising a compound of formula (I) as defined in any one of claims 1 to 10, or a salt, solvate or stereoisomer thereof, and at least one pharma- ceutically acceptable excipient.
13. A pharmaceutical composition comprising a compound of formula (I) as defined in any one of claims 1 to 10, or a salt, solvate or stereoisomer thereof, for use in the treatment or prevention of a HDAC6-related disease or disorder.
14. The pharmaceutical composition according to claim 13, wherein the HDAC6-associated disease or disorder is a central nervous system HDAC6-associated disease or disorder.
Citation Information
Patent Citations
1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions containing the same , and the Pharmaceutical Composition Comprising the same)
JP2018521092A
1,3,4-oxadiazole amide derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions containing the same
JP2018521110A
1,3,4-oxadiazole derivative compound as a histone deacetylase 6 inhibitor and a pharmaceutical composition containing the same
JP2018523663A
1,3,4-oxadiazolesulfonamide derivative compound as a histone deacetylase 6 inhibitor and a pharmaceutical composition containing the same
JP2018526343A
Compounds and methods
WO2013066838A1
